The agenda includes:
Preparing a position on the evaluation of the drug Vimetso (vildagliptin + metformin hydrochloride) for the indication: treatment of type 2 diabetes mellitus.
Preparation of opinions on the legitimacy of granting reimbursement from public funds of medicines containing the active substance lenalidomide in combination with:
- rituximab for the indication: treatment of adult patients with previously untreated grade 1-3a lump lymphoma,
- rituximab for the indication: treatment of adult patients with previously treated marginal zone lymphomas,
- rituximab for the indication: treatment of adult patients with relapsed or refractory mantle cell lymphoma,
- Tafasitamab for the indication: treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous haematopoietic stem cell transplantation.
Preparation of opinions on draft health policy programmes of local government units:
- “Chance of parenthood for the residents of the Opolskie Voivodeship in the scope of support of infertility diagnosis and treatment”.
- “Health policy programme on vaccination against meningococcus type B carried out among children aged 2 months to 12 months born on the territory of the Municipality of Miękinia for the years 2023-2026”.